Format
Sort by

Send to:

Choose Destination

Results: 5

1.

What is recent in pancreatic cancer immunotherapy?

Niccolai E, Prisco D, D'Elios MM, Amedei A.

Biomed Res Int. 2013;2013:492372. doi: 10.1155/2013/492372. Epub 2012 Dec 26. Review.

PMID:
23509731
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL.

J Immunother. 2013 Jan;36(1):29-40. doi: 10.1097/CJI.0b013e3182780f61.

PMID:
23211623
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.

Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS, Bartlett DL, Fu N, He Y.

J Immunol. 2011 Aug 15;187(4):1788-96. doi: 10.4049/jimmunol.1101138. Epub 2011 Jul 11.

PMID:
21746967
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Potential targets for pancreatic cancer immunotherapeutics.

Dodson LF, Hawkins WG, Goedegebuure P.

Immunotherapy. 2011 Apr;3(4):517-37. doi: 10.2217/imt.11.10. Review.

PMID:
21463193
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Stimulation of anti-tumor immunity by photodynamic therapy.

Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR.

Expert Rev Clin Immunol. 2011 Jan;7(1):75-91. doi: 10.1586/eci.10.81. Review.

PMID:
21162652
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk